Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19105490 | 1.00 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 | |
| SCHEMBL19105487 | 1.00 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 | |
| SCHEMBL8259613 | 0.98 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL7850115 | 0.98 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL25616710 | 0.98 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL23588767 | 0.98 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL8260721 | 0.98 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL19699827 | 0.96 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL24854010 | 0.96 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL8257116 | 0.89 | TLR9 (0.35) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11827646-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827646-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| EP-4241772-A2 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2023-09-13 | — | — | EP | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| EP-3663296-B1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2023-05-17 | — | — | EP | disclosed |
| WO-2021234181-A1 | USE OF FAP INHIBITOR IN A METHOD OF DIAGNOSIS | Universität Heidelberg (DE) | 2021-11-25 | — | — | WO | disclosed |
| US-8067590-B2 | Melanin-concentrating hormone (MCH) receptor antagonists; treating obesity, eating disorders, affective disorders, drug dependency; compounds are amino-functional pyridazin-3-one, 1H-pyridin-2-one or 3H-pyrimidin-4-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110195934-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7524862-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-28 | — | — | US | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | L3MBTL3 1436/4885L3MBTL1 1242/4885MBTD1 1005/4885 |
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | L3MBTL3 3906/4885L3MBTL1 4015/4885MBTD1 4148/4885 |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | L3MBTL3 306/4885L3MBTL1 300/4885MBTD1 2471/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | L3MBTL3 2963/4885L3MBTL1 1959/4885MBTD1 4215/4885 |
| US-20110195934-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MC1R, MCHR1, MCHR2 | L3MBTL3 4349/4885L3MBTL1 3222/4885MBTD1 1262/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | L3MBTL3 518/4885L3MBTL1 228/4885MBTD1 2125/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | L3MBTL3 3020/4885L3MBTL1 2568/4885MBTD1 346/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | L3MBTL3 2598/4885L3MBTL1 2048/4885MBTD1 486/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | L3MBTL3 1663/4885L3MBTL1 1271/4885MBTD1 2387/4885 |
| US-11827646-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | L3MBTL3 3589/4885L3MBTL1 3095/4885MBTD1 3699/4885 |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | L3MBTL3 118/4885L3MBTL1 92/4885MBTD1 2090/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | L3MBTL3 2301/4885L3MBTL1 2500/4885MBTD1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.